AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease
Institute for Molecular Medicine
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease. Approximately 160 participants will be randomized to receive AV-1959R or placebo and will be followed for 78 weeks. The study will assess safety, immune responses, brain amyloid, and Alzheimer's disease-related biomarkers.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- AREVIA
- status
- NOT_YET_RECRUITING
- phase
- PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 160
- sponsor
- Institute for Molecular Medicine
- conditions
- Preclinical Alzheimer's Disease; Alzheimer Disease
- interventions
- BIOLOGICAL: AV-1959R; DRUG: Placebo
- start date
- 2027-10-01
- start date type
- ESTIMATED
- primary completion date
- 2029-10-15
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07827768
- Published
- Sep 18, 2026
- Updated
- Oct 21, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07827768
- Categories
- Preclinical Alzheimer's Disease, Alzheimer Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials